Herspiegel Consulting
Industry Leader – Pharmaceutical & Biotech Consulting
We are a full service pharmaceutical and biotech consulting firm that specializes in new product planning and commercial expertise to optimize product launches and brand performance. Our diverse team has a combined 100+ years of extensive corporate, client and consulting experience in biopharmaceuticals. We leverage our expertise to solve critical business issues, deliver innovative solutions and develop best-in-class deliverables to optimize the value of your brands.
At Herspiegel Consulting, we offer a range of integrative pharmaceutical consulting services, tailored and scaled to meet your brand and business’ needs across a wide variety of therapeutic areas. Our services include pharmaceutical new product planning, product launch preparation, marketing excellence, market access strategy, and market shaping. Industry focus and depth of functional expertise, combined with strong scientific and market knowledge, uniquely position our team to develop achievable strategies and solutions for our clients.
Explore Our Capabilities
Learn how our customized services can help you meet your brand goals.
Hear Our Perspectives
Read our blogs and white papers to learn what’s happening in the healthcare industry.
Get In Touch
Contact us to learn how Herspiegel Consulting can help your organization.
Latest Blogs
Planning for 505(b)2 Commercial Success
October 17, 2018Unlike generics and biosimilars, 505(b)2 regulatory products likely involve a unique claim. While 505(b)...
Read more
Fed-Up Hospitals are Starting Their Own Drug Company to Lower Generic Drug Prices
February 12, 2018The impact of drug shortages is not new within the healthcare system, particularly at the hospital level...
Read more
FDA Continued Rejections of Citizen Petitions Highlights Key Lifecycle Challenges for Biologic Manufacturers
January 24, 2018Citizen petitions have historically been a tool in the brand manufacturer’s toolkit of “product life...
Read more
The FDA approved Dupixent for moderate-to-severe atopic dermatitis
April 14, 2017 The FDA approved Dupixent On March 28th, the FDA approved Dupixent for moderate-to-severe atopic ...
Read more